HSPG2 and hepatocellular carcinoma: To test whether siGRP modified exosomes showed functional activity in inhibiting Sorafenib sensitive and resistant HCC cell growth, we treated Sorafenib-sensitive or resistant HepG2 or PLC cells for 48 h with 0.1, 0.5, 1 or 10 μg/ml of exosomes with scrambled siRNA or with siGRP78 and combined with or without Sorafenib (HepG2 was 10 μM, and PLC was 12.5 μM).